CG Oncology expands ATM offering by $500M to up to $1.05B total after selling 10.8M shares at $72.42

Filed August 6, 2026 · ~1 min read

Key Changes

• high

  CG Oncology completed its original $550M ATM program by selling 10.8M shares and is now expanding the facility by an additional $500M, bringing total authorized offering size to up to $1.05B. Shares are sold opportunistically through Jefferies as sales agent at prevailing market prices.

  The Offering verify on EDGAR →
• high

  At the August 5, 2026 market price of $72.42/share, new investors face immediate dilution of $56.91 per share (78% of the offer price). The company's net tangible book value per share is substantially below the market price.

  Dilution verify on EDGAR →
• medium

  Net proceeds will fund cretostimogene research and development including regulatory approval efforts, commercialization preparation (subject to approval), capital expenditures, general and administrative costs, and working capital. No specific dollar amounts are allocated to any category.

  Use of Proceeds verify on EDGAR →